News

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

PURCHASE, N.Y., Nov. 15, 2021 — Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the closing of an additional 565,217 shares of its common …

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering Read More »

Cognition Therapeutics Announces Launch of its Initial Public Offering

Purchase, NY, Oct. 04, 2021 — Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced that it has launched an initial public offering of 3,350,000 shares of …

Cognition Therapeutics Announces Launch of its Initial Public Offering Read More »

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

Pittsburgh, January 5, 2021 – Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and providing an on-demand company presentation. In addition, Ms. Ricciardi will be participating in …

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance Read More »

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

Pittsburgh, October 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors. Dr. Monia is a founding member and the current CEO of Ionis Pharmaceuticals, a pioneer in …

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors Read More »

Scroll to Top